Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lemaitre Vascular (LMAT) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Lemaitre Vascular (LMAT) over the last 16 years, with Q3 2025 value amounting to $6.6 million.

  • Lemaitre Vascular's Change in Accured Expenses rose 26620.27% to $6.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.1 million, marking a year-over-year increase of 377202.07%. This contributed to the annual value of -$779000.0 for FY2024, which is 11693.85% down from last year.
  • Lemaitre Vascular's Change in Accured Expenses amounted to $6.6 million in Q3 2025, which was up 26620.27% from $4.0 million recorded in Q2 2025.
  • In the past 5 years, Lemaitre Vascular's Change in Accured Expenses registered a high of $6.6 million during Q3 2025, and its lowest value of -$5.3 million during Q1 2025.
  • Over the past 5 years, Lemaitre Vascular's median Change in Accured Expenses value was $469000.0 (recorded in 2022), while the average stood at $424105.3.
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first tumbled by 23723.49% in 2021, then skyrocketed by 915714.29% in 2023.
  • Over the past 5 years, Lemaitre Vascular's Change in Accured Expenses (Quarter) stood at -$1.2 million in 2021, then soared by 140.19% to $469000.0 in 2022, then skyrocketed by 400.21% to $2.3 million in 2023, then fell by 24.98% to $1.8 million in 2024, then skyrocketed by 273.69% to $6.6 million in 2025.
  • Its Change in Accured Expenses was $6.6 million in Q3 2025, compared to $4.0 million in Q2 2025 and -$5.3 million in Q1 2025.